Skip to main content
All lobbying filings

BIOGEN

Lobbying for BIOGEN

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $1,460,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 11
  • S 864
    HELP Copays Act
  • HR 6130
    ASAP Act
  • S 3267
    ASAP Act
  • HR 3747
    AADAPT Act
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
  • HR 4317
    PBM Reform Act of 2025
  • S 3345
    PBM Price Transparency and Accountability Act
  • HR 6837
    To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fi…
  • HR 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
  • S 832
    EPIC Act of 2025
  • HR 946
    ORPHAN Cures Act
 Lobbying activity 5
Medicare/Medicaid

Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.

Health Issues

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education

Pharmacy

Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act

Taxation/Internal Revenue Code

Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.

Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property, no related bills

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem